Andre Iguodala out for Golden State in Game 1 of NBA Finals

admin rysqjljcpzpp , , , , , , , , , , , , , ,

first_imgIn fight vs corruption, Duterte now points to Ayala, MVP companies as ‘big fish’ Steam emission over Taal’s main crater ‘steady’ for past 24 hours Golden State Warriors’ Andre Iguodala smiles as he answers questions after an NBA basketball practice, Wednesday, May 30, 2018, in Oakland, Calif. The Warriors face the Cleveland Cavaliers in Game 1 of the NBA Finals on Thursday in Oakland. (AP Photo/Marcio Jose Sanchez)OAKLAND, Calif. — Golden State forward Andre Iguodala will miss Game 1 of the NBA Finals as he recovers from a bone bruise in his left knee that cost him the last four games of the Western Conference finals.Iguodala’s absence is a huge blow to the Warriors’ defense as it works to stop LeBron James and the Cleveland Cavaliers. Golden State coach Steve Kerr said several players will be called upon Thursday to handle the load that is James, making his eighth straight finals appearance.ADVERTISEMENT Kevon Looney has been starting in Iguodala’s place.Looney planned to talk to Iguodala about the task of guarding James.“I’ll pick his brain about some things … some tendencies of LeBron, the fact of the switches or small things like that to help me out,” Looney said. “He’s one of the best defenders in the league.”That’s why everybody on the Warriors realizes it will be a joint effort guarding James.“What he brings to us on the defensive end will definitely be missed,” Green said. “But it just means other guys have got to step up. Other guys have done that thus far. The task gets even harder but I know guys will and it will be a collective effort in hopes that we keep trekking along until he’s ready to come back.”ADVERTISEMENT Winfrey details her decision to withdraw from Simmons film Dave Chappelle donates P1 million to Taal relief operations Forward Kevin Love’s status for Cleveland remained unclear as he continues to go through the NBA’s concussion protocol. Love was injured in Game 6 of the Eastern Conference finals against Boston that the Cavs pulled out in seven. He wasn’t scheduled to attend media day Wednesday at Oracle Arena, where the Warriors host the series opener in the fourth straight finals meeting between the rivals.“He’s going to go do some things today and see how he feels,” Cavs coach Tyronn Lue said. “But he is in the protocol still, so we’ll see how he feels.”Both teams practiced Wednesday on Golden State’s home floor, where the defending champions have won 17 of their last 18 postseason games.James certainly understands what the Warriors are missing without Iguodala’s presence and athleticism.“First of all he has very, very quick hands,” James said. “That doesn’t get talked about a lot, his ability to read and react to the ball either in flight or while you’re dribbling or when you pick the ball up.”Sports Related Videospowered by AdSparcRead Next A win, finally “He was MVP of the series in 2015, largely because he took that role on of guarding LeBron. But also because of what he did offensively,” Kerr said. “He’s doing a little bit better today. Some encouraging signs, but we have ruled him out for Game 1. We’ve got lots of guys who can take on that job. It’s a group effort, anyway, guarding LeBron. So, KD (Kevin Durant), Draymond (Green), Klay (Thompson), Shaun Livingston, they’ll all see time on him.”The Warriors said Iguodala, who was injured in Game 3 against the Rockets on May 20, was evaluated Tuesday and is making progress but still has the bruise and inflammation of the nerve surrounding his knee. Kerr has said Iguodala wouldn’t play until he can run without pain. He will be re-evaluated ahead of Sunday’s Game 2.FEATURED STORIESSPORTSGinebra beats Meralco again to capture PBA Governors’ Cup titleSPORTSAfter winning title, time for LA Tenorio to give back to Batangas folkSPORTSTim Cone, Ginebra set their sights on elusive All-Filipino crownIguodala said he doesn’t have any doubts he will be able to return during the finals, though his patience is tested. He has sought multiple opinions for the injury.“Just trying to figure out how to move in general,” Iguodala said. “But making some progress. Slower than we expected but we’re just being realistic.” China population now over 1.4 billion as birthrate falls Jury of 7 men, 5 women selected for Weinstein rape trial Carpio hits red carpet treatment for China Coast Guard PLAY LIST 02:14Carpio hits red carpet treatment for China Coast Guard02:56NCRPO pledges to donate P3.5 million to victims of Taal eruption00:56Heavy rain brings some relief in Australia02:37Calm moments allow Taal folks some respite03:23Negosyo sa Tagaytay City, bagsak sa pag-aalboroto ng Bulkang Taal01:13Christian Standhardinger wins PBA Best Player award MOST READ Lights inside SMX hall flicker as Duterte rants vs Ayala, Pangilinan anew LATEST STORIES View comments Nadine Lustre’s phone stolen in Brazil Don’t miss out on the latest news and information. Volcano watch: Island fissures steaming, lake water recedinglast_img

You May Also Like..

FBC Holdings Limited (FBC.zw) 2011 Abridged Report

first_imgFBC Holdings Limited (FBC.zw) listed on the Zimbabwe Stock Exchange under the Banking sector has released it’s 2011 abridged results.For more information about FBC Holdings Limited (FBC.zw) reports, abridged reports, interim earnings results and earnings presentations, visit the FBC Holdings Limited (FBC.zw) company page on AfricanFinancials.Document: FBC Holdings Limited (FBC.zw)  2011 abridged results.Company ProfileFBC Holdings Limited (FBC Bank) is a financial institution in Zimbabwe providing financial products and solutions for retail, commercial and corporate banking; with a range of products and services extending from savings deposit accounts and micro-lending in the informal market to foreign market investment, mortgage financing, micro-lending, re-insurance, short-term insurance and stock-brokering services. Its re-insurance division underwrites classes of insurance for fire, engineering, motoring, marine and miscellaneous incidences. FBC Bank is a wholly-owned subsidiary of First Banking Corporation Holdings Limited which is a publicly-traded financial services company in Zimbabwe. FBC Holdings Limited is listed on the Zimbabwe Stock Exchangelast_img

The price of this UK tech share is up over 80% in just the last month. Would I buy?

first_img There’s a perception that the US has all the high-growth technology stocks in the US and that UK tech shares tend to be bought by overseas companies. For example, SoftBank bought ARM Holdings back in 2016. And now Nvidia is taking it over. However, the UK does have listed technology shares. One of these shares is artificial intelligence company RenalytixAI (LSE: RENX). The share price has leapt recently, which raises the question: could the shares rocket further or are they now too expensive?5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…What does the company do?First of all, let’s look at what it does. RenalytixAI provides artificial intelligence-based diagnostics for kidney disease through its KidneyIntelX platform. The algorithm combines data in order to provide a patient risk score which then helps doctors treat patients better.It has a niche which is actually quite a large addressable market, especially in the US. Chronic kidney conditions there affect 15% of adults or 37m people. This costs Medicare over $120bn per year.Obviously, the problem stretches beyond the US and is global, so there’s a huge potential market for an AI diagnostics tool to help doctors.Why has the share price risen and what’s the opportunity for future growth?I think it’s the potential for the company to get approval from the US Food and Drug Administration (FDA) that is boosting the shares. Approvals to sell its tests at $950 a time to healthcare facilities across the US could be transformative for the company, which makes no revenue for now. An update is expected within the coming months, hence the share price leap. Beyond the immediate prospect of the FDA announcement, the AI company has partnerships with AstraZeneca and Mount Sinai in the US. The latter is a joint venture for a Covid-19 test, which could be rolled out globally. That could be another source of revenue in the future. Longer term, if RenalytixAI can roll out successfully across the US there could be huge opportunities in other international markets. Also in the future, there will almost certainly be more chances to apply artificial intelligence to other healthcare problems. Once the technology is accepted and trusted there will be a lot of other opportunities to cut healthcare costs and improve outcomes for patients. Spending on solutions at that point should accelerate quickly. What will I do with this UK tech share?For now when it comes to the share price, I’ll wait and see. When a share price rises this much in such a short space of time there’s certainly more risk. I worry I may be late to the party and arrive just as the share price starts to revert back towards more usual levels. I’ll add the UK tech share to my watchlist and see what happens next. It’s possible, of course, the FDA might not rule in favour of RenalytixAI, or other operational hurdles may appear. That’s why I remain quietly optimistic, but also cautious. Andy Ross owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Image source: Getty Images. Enter Your Email Address I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Our 6 ‘Best Buys Now’ Shares Get the full details on this £5 stock now – while your report is free. Andy Ross | Saturday, 30th January, 2021 | More on: RENX center_img Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. The price of this UK tech share is up over 80% in just the last month. Would I buy? Are you on the lookout for UK growth stocks?If so, get this FREE no-strings report now.While it’s available: you’ll discover what we think is a top growth stock for the decade ahead.And the performance of this company really is stunning.In 2019, it returned £150million to shareholders through buybacks and dividends.We believe its financial position is about as solid as anything we’ve seen.Since 2016, annual revenues increased 31%In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259Operating cash flow is up 47%. (Even its operating margins are rising every year!)Quite simply, we believe it’s a fantastic Foolish growth pick.What’s more, it deserves your attention today.So please don’t wait another moment. Simply click below to discover how you can take advantage of this. FREE REPORT: Why this £5 stock could be set to surge See all posts by Andy Rosslast_img

This is what I’m doing about the [email protected] Capital share price right now

first_img Enter Your Email Address The high-calibre small-cap stock flying under the City’s radar Image source: Getty Images See all posts by Rupert Hargreaves I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Adventurous investors like you won’t want to miss out on what could be a truly astonishing opportunity…You see, over the past three years, this AIM-listed company has been quietly powering ahead… rewarding its shareholders with generous share price growth thanks to a carefully orchestrated ‘buy and build’ strategy.And with a first-class management team at the helm, a proven, well-executed business model, plus market-leading positions in high-margin, niche products… our analysts believe there’s still plenty more potential growth in the pipeline.Here’s your chance to discover exactly what has got our Motley Fool UK investment team all hot-under-the-collar about this tiny £350+ million enterprise… inside a specially prepared free investment report.But here’s the really exciting part… right now, we believe many UK investors have quite simply never heard of this company before! Simply click below to discover how you can take advantage of this.center_img This is what I’m doing about the [email protected] Capital share price right now Click here to claim your copy of this special investment report — and we’ll tell you the name of this Top Small-Cap Stock… free of charge! I think the [email protected] Capital (LSE: SYME) share price has tremendous potential. This is something I have flagged in previous articles when looking at the size of the company’s total addressable market. The size of the inventory finance market, where the fintech firm focuses its efforts, is over $1trn. [email protected] is one of the leading players in the European market for inventory [email protected] Capital share price suspension Unfortunately, market sentiment towards the business has been hurt recently by the company’s own mistakes. After changing its financial reporting calendar, management had to request a temporary suspension of trading in the company’s s shares, pending publication of its 31 December 2019 year-end accounts and its 2020 interim results for the six months ended 30 June.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…Trading was restored at the beginning of March, and according to management, the underlying business hasn’t been affected. However, a trading suspension is a big red flag. It should be something companies try to avoid at all costs.This has made me think that if management has made this fundamental mistake, what other errors are hidden away in the cupboard? That said, aside from this issue, it looks as if the rest of the business is firing on all cylinders. That’s why I’m excited about the outlook for the [email protected] Capital share price. Revenue growth The group recently announced that it had signed heads of terms to acquire the leading, Singapore-based fintech-powered commodities trade enabler, TradeFlow Capital Management Pte Ltd.What’s more, according to [email protected]’s interim results to June 2020, its number of client companies increased from 82 at the end of the first quarter of 2020 to 165 by the end of the year.Meanwhile, the gross origination of client companies increased 30% between September and the end of December 2020. Turnover in the six months to 30 June 2020 increased to £368k, up from £11k in the same period a year ago. This resulted in a gross profit of £368k, the same as the turnover figure. But after including all administrative expenses and exceptional costs, the group reported a loss for the period of £2.1m. Looking at these results, I’m excited to see what the future holds for the company. If growth continues, the outlook for the [email protected] Capital share price seems incredibly bright. Risks and challenges However, much depends on the company’s ability to continue to attract lenders to its platform. Supply has done a solid job of attracting borrowers and creditors to its platforms so far. There’s no guarantee this trend will continue.What’s more, the company is losing money and relies on shareholders to keep the lights on. If investor sentiment towards the enterprise falls substantially, it may become harder for the business to raise funding. That could jeopardise its future.Overall, I’m cautiously optimistic about the outlook for the [email protected] Capital share price. As such, I would add the stock to my portfolio, but only in a limited way considering the enterprise’s risks and challenges.  Rupert Hargreaves | Wednesday, 31st March, 2021 | More on: SYME Our 6 ‘Best Buys Now’ Shares Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee.last_img

Leave a Reply

Your email address will not be published. Required fields are marked *